Weight Loss Programs

Now Offering: Daily Oral Sublingual Weight Loss Drops & Weekly Injectables
We're excited to offer both oral sublingual weight loss drops (taken daily) and injectable treatments (administered weekly) to support your personalized weight loss journey. These options are ideal for those looking for flexibility and science-backed results, whether you prefer the convenience of a daily routine or the simplicity of a once-weekly injection.

⚠️ Availability is limited (On injectables) due to recent FDA court rulings affecting compounding regulations—products are offered while supplies last.

Don't wait—reach out today to explore the best option for your goals and lifestyle.

FDA-Approved Injectable Weight Loss Treatment: 

Compounded Semaglutide, is a game-changer for weight loss. This injectable prescription mimics GLP-1 (glucagon-like peptide-1), a hormone that regulates appetite and blood sugar. It works by blocking Ghrelin—the “hunger hormone”—so you feel fuller, longer.  Originally designed for type 2 diabetes, Semaglutide also helps control blood sugar by stimulating insulin release. The best part? Just one injection per week—no daily pills or multiple doses to keep track of!  If you're looking to commit to the science-backed way to manage weight and hunger, Semaglutide might be the solution.  

 FDA-Approved Injectable Weight Loss Treatment:
Compounded Tirzepatide, represents a breakthrough in medical weight loss. This once-weekly injectable mimics not one, but two hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—which together regulate appetite, insulin production, and blood sugar levels more effectively than previous treatments.

Tirzepatide not only helps you feel full longer by slowing gastric emptying and reducing hunger hormones like ghrelin, but it also enhances insulin sensitivity and supports steady blood sugar control. Originally developed for type 2 diabetes, it has demonstrated significant weight loss benefits, leading to its FDA approval specifically for chronic weight management.

If you're ready to take a science-driven, highly effective approach to weight loss, Tirzepatide may be the solution you've been waiting for.

Semaglutide and Tirzepatide drops, while gaining popularity in the weight loss market, are not currently approved by the U.S. Food and Drug Administration (FDA) in their drop formulations. Although both medications are FDA-approved for specific injectable treatments related to diabetes and, in some cases, chronic weight management, their use as compounded oral drops has not undergone the rigorous testing and regulatory review required for FDA approval. 

 While compounded oral versions of semaglutide and tirzepatide are not FDA-approved, there is ongoing research into their potential. Novo Nordisk has submitted a marketing application for an oral version of semaglutide, which, if approved, would become the first oral GLP-1 therapy for chronic weight management in the U.S. The FDA has accepted this application, and a decision is expected later in 2025 . Similarly, Eli Lilly is developing an oral GLP-1 medication, orforglipron, which has shown promising results in clinical trials . These developments indicate a shift towards more convenient oral formulations, but until FDA approval is granted, compounded versions of these drugs remain unapproved and carry potential risks. 

With my pharmacy, they take immense pride in upholding the highest standards of safety, quality, and regulatory compliance. Every product they dispense is sourced, prepared, and handled in accordance with strict federal and state guidelines, ensuring our patients receive only the safest and most effective medications. This facility is meticulously maintained to exceed industry cleanliness standards, and our team of licensed pharmacists and technicians are dedicated to continuous education and precision in compounding practices. They and myself are committed to transparency, patient safety, and excellence—because you deserve a pharmacy you can trust. 

• Weight loss
• Lowers blood sugar
• Lowers blood pressure
• Lowers cholesterol 
• Lowers risk of heart disease 

• Weekly or Monthly check-in appointments
• Yearly laboratory levels 
• Pregnancy test initially, if applicable. (This medication is not suitable for pregnant or nursing women)

• Clear your mind
• Maintain adequate protein goals
• Increase your water intake
• Make a list and prep for success
• Set attainable goals
• Eat healthy foods- protein, fiber, fats
• Get moving (in the right direction!)
• Commit to change 

Like all medications, Semaglutide can cause side effects. The most common are gastrointestinal symptoms:

• Nausea
   
• Vomiting
   
• Diarrhea
   
• Abdominal pain
   
• Constipation
   

Less common but serious risks may include:

• Pancreatitis (inflammation of the pancreas)
   
• Vision changes (especially in those with diabetes)
   
• Hypoglycemia (especially when combined with other diabetes medications)
   
• Kidney problems due to dehydration from vomiting/diarrhea
   

Semaglutide is not suitable for:

• Individuals with a personal or family history of medullary thyroid carcinoma (MTC)
   
• Those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
   
• Patients with severe gastrointestinal disorders, such as gastroparesis
   
• People under 18 years old, as safety is not established in this group
   

💡 It is crucial to discuss all potential risks with a healthcare provider before starting treatment with Semaglutide.
 

Tirzepatide shares some side effects with Semaglutide but also has unique considerations due to its dual hormone action (GLP-1 and GIP). Common side effects include:

• Nausea
   
• Diarrhea
   
• Decreased appetite
   
• Vomiting
   
• Constipation
   
• Indigestion
   
• Fatigue
   

Potential serious side effects:

• Pancreatitis
   
• Severe gastrointestinal issues, such as intestinal blockage
   
• Thyroid C-cell tumors (seen in animal studies)
   
• Gallbladder disease
   
• Low blood sugar, especially with insulin or sulfonylureas
   
• Allergic reactions
   

Tirzepatide should not be used by:

• Individuals with a personal or family history of medullary thyroid carcinoma (MTC)
   
• Those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
   
• Patients with a history of severe GI disorders, such as gastroparesis
   
• People under 18 years old, as it is not approved for pediatric use
   

💡 As with any medication, a thorough consultation with a healthcare provider is essential before starting Tirzepatide.